MYD88 and diffuse large B-cell lymphoma: In this regard, a striking feature of our results is the finding that in our population-based patient cohort SPIBhigh/BATFlow-ABC-DLBCLs with a MYD88-L265P mutation, detectable by Sanger sequencing, identifies a distinct group of ABC-DLBCL with a favourable outcome on current therapy.